Bottom line
What is LABFX's expense ratio?
LABFX's expense ratio is 1.31%, or about $131 a year on every $10,000 invested. That is more expensive than 79% of allocation / balanced funds we track (median 0.91%). This share class also charges a front-end sales load of up to 2.25%, taken from your investment when you buy. Its expense ratio includes a 0.25% 12b-1 marketing fee.
Updated Apr 24, 2026
LABFX fee table
| Net expense ratio | 1.31% |
|---|---|
| Gross expense ratio | 1.31% |
| Management fee | 0.1% |
| 12b-1 (distribution) fee | 0.25% |
| Other expenses | 0.15% |
| Acquired fund fees | 0.81% |
| Max front-end sales load | 2.25% |
| Max deferred sales charge | 0% |
Source: Fund prospectus fee table, filed Apr 24, 2026
What LABFX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| LABFX | $355 | $631 | $927 | $1,768 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 1.31% expense ratio costs roughly $70,600 in lost growth, versus about $50,800 for the median allocation / balanced fund (0.91%).